The Motley Fool
11 Jul 2026, 20:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The European Medicines Agency recommended that Acadia Pharmaceuticals' drug Daybue be allowed for sale in the European Union. — Regulatory approval in a major market like the EU significantly expands the addressable market and revenue potential for a drug.
+0.80Acadia Pharmaceuticals reported first-quarter 2026 revenue of $268.1 million, an increase from $244.3 million the prior year. — Consistent year-over-year revenue growth indicates positive business momentum and commercial execution.
+0.30Principal Accounting Officer James Kihara sold 11,421 shares of ACAD, representing 46.6% of his holdings. — While a significant reduction in insider holdings can be a bearish signal, the sale was part of a pre-established 10b5-1 plan, reducing its predictive value.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
Positive news regarding European Medicines Agency recommendation and revenue growth, though slightly offset by a significant insider sale.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
3h ago
